• Vijaykumar Patil Faculty of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur
  • Deepak Belsare NDMVP Samaj's College of Pharmacy, Nasik


Objective: Tolterodine tartrate (tolterodine) is used for treating overactive bladder (OAB) with symptoms of urinary frequency, urgency and leakage. Tolterodine is an antimuscarinic (anticholinergic) agent. It works by blocking a chemical that causes contractions of the bladder. Present work involved development of a novel drug delivery system of tolterodine intended to be taken once daily.

Methods: Extended release (ER) pellets of tolterodine were prepared and optimized for in vitro drug release. Subsequently, these pellets were filled into a suitable sized capsule. The resulting capsules were evaluated for in vitro drug release. Optimized formulation was subjected to accelerated stability studies for 3 mo and was evaluated for description, average weight, assay and drug release.

Results: The optimized ER capsule exhibited similar dissolution profile as that of the reference listed drug (RLD), with approximately 45%, 75% and more than 80% release in 3 h, 5 h and 7 h respectively. Accelerated stability studies indicated good physical and chemical stability of the formulation.

Conclusion: ER formulation of tolterodine was optimized and can be used as once a day dosage, reducing the frequency of administration when compared with the immediate release formulation. The developed formulation exhibited similar behavior as that of reference formulation Detrol LA marketed in the US.

Keywords: Tolterodine, ER, Surelease, Osmogent, Detrol LA


1. Patient information leaflet Detrol® LA capsules submitted to US FDA- reference ID - 3168106
2. Center for drug evaluation and research, medical review: application no. 21-228 S006. Applicant: Pharmacia & Upjohn Company.
3. Product monograph Detrol® LA , Pfizer Canada Inc., Submission Control No: 180260
4. Umesh Nandkumar Khatavkar, K Jayaram Kumar, Shamkant Laxman Shimpi. Novel approaches for the development of oral controlled release compositions of galantamine hydrobromide and paroxetine hydrochloride hemihydrate: a review. Int J Appl Pharm 2016;8:1-6

5. Panchaxari mallappa dandagi, Chirag prakashbhai patel, Rohit sharma, Anand panchakshari gadad, Vinayak mastiholimath. Studies on formulation and evaluation of osmotically controlled drug delivery system of Carbamazepine. Int J Pharm Pharm Sci 2014;6:239-50
6. Dehghan MHG, Kazi MS, Ansari MA. Formulation and evaluation of once daily osmotic tablet of Ketoprofen. Int J Pharm Pharm Sci 2014;6:951-57
7. Borra SP et al., Formulation of Tolterodine Tartrate Controlled Release MUPS Tablets by Using Novel Core and Studying the Effect of Protective Plasticizer. Am J PharmTech Res 2016;6:632-50
242 Views | 945 Downloads
How to Cite
Patil, V., & Belsare, D. (2017). DEVELOPMENT AND EVALUATION OF NOVEL DRUG DELIVERY SYSTEM OF TOLTERODINE TARTRATE. International Journal of Applied Pharmaceutics, 9(5), 29-32.
Original Article(s)